PDCD1 and neoplasm: Similar findings were obtained by combining a PD-1 blocker plus recombinant fms related receptor tyrosine kinase 3 ligand (FLT3LG) – together mediating a minimal activity on tumor growth and OS – with focal RT delivered in 3 fractions of 10 Gy.